肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

2019年ASCO：Vofatamab治疗晚期尿路上皮细胞癌（膀胱癌）患者的全新数据

2019-02-19 不详 网络

尿路上皮细胞癌Vofatamab膀胱癌
关注

Rainier是一家临床阶段的药物开发公司，近日在2019年ASCO上公布了Vofatamab（一种成纤维细胞生长因子受体3（FGFR3）靶向抗体）的II期临床试验（FIERCE-21试验）的初步数据。这项研究正在评估Vofatamab与多西他赛组合疗法治疗FGFR3突变的局部晚期或转移性膀胱癌患者的有效性和安全性。

Rainier是一家临床阶段的药物开发公司，近日在2019年ASCO上公布了Vofatamab（一种成纤维细胞生长因子受体3（FGFR3）靶向抗体）的II期临床试验（FIERCE-21试验）的初步数据。这项研究正在评估Vofatamab与多西他赛组合疗法治疗FGFR3突变的局部晚期或转移性膀胱癌患者的有效性和安全性。

Rainier首席医疗官Steve Abella博士说：“我们对FIERCE-21试验中的这些初步数据表示满意，这些数据表明，Vofatamab联合多西他赛能够在非常晚期的患者中提供临床益处。此外，在经过严格预处理的患者组中，Vofatamab也观察到单药活性。我们期待在今年晚些时候报告进一步的数据”。

膀胱癌泛指各种出自膀胱的恶性肿瘤，也就是有异常细胞大量增殖而不受管制。膀胱是贮存尿液的中空器官，外壁主要由肌肉构成，位于下腹部。最常见的膀胱癌细胞来自膀胱内面黏膜表皮，正式名称为移行上皮细胞癌（TCC）。


原始出处：

http://www.firstwordpharma.com/node/1625456?tsid=4#axzz5fsFeuq5D

本文系梅斯医学（MedSci）原创编译整理，转载需授权!

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-03-19 jxrzshh

    #尿路上皮细胞癌#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-11-07 snf701207

    #mAb#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-03-10 qingting

    #细胞癌#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-10-08 12498bd5m16暂无昵称

    #fat#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-11-07 quxin068

    #ASC#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-21 bbjsj_1981

    #ATA#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-21 lizhou0208

    #上皮细胞#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1967394, encodeId=4043196e394a0, content=<a href='/topic/show?id=06044e51700' target=_blank style='color:#2F92EE;'>#尿路上皮细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=47517, encryptionId=06044e51700, topicName=尿路上皮细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Tue Mar 19 14:41:00 CST 2019, time=2019-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1912088, encodeId=36cc19120880f, content=<a href='/topic/show?id=4de7112046c' target=_blank style='color:#2F92EE;'>#mAb#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11204, encryptionId=4de7112046c, topicName=mAb)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Thu Nov 07 09:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1978811, encodeId=d7fc19e88119e, content=<a href='/topic/show?id=3b90e79787f' target=_blank style='color:#2F92EE;'>#细胞癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77978, encryptionId=3b90e79787f, topicName=细胞癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e457184, createdName=qingting, createdTime=Sun Mar 10 10:41:00 CST 2019, time=2019-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2029955, encodeId=a3712029955e1, content=<a href='/topic/show?id=d493e259c9' target=_blank style='color:#2F92EE;'>#fat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7259, encryptionId=d493e259c9, topicName=fat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=198d2500149, createdName=12498bd5m16暂无昵称, createdTime=Tue Oct 08 21:41:00 CST 2019, time=2019-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938925, encodeId=e0031938925d7, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Thu Nov 07 07:41:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1466076, encodeId=5e1814660e6b5, content=<a href='/topic/show?id=217c292009' target=_blank style='color:#2F92EE;'>#ATA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2920, encryptionId=217c292009, topicName=ATA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=387a6772119, createdName=bbjsj_1981, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1533886, encodeId=6b6915338868e, content=<a href='/topic/show?id=4be9200308c' target=_blank style='color:#2F92EE;'>#上皮细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20030, encryptionId=4be9200308c, topicName=上皮细胞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a5d12492718, createdName=lizhou0208, createdTime=Thu Feb 21 09:41:00 CST 2019, time=2019-02-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361111, encodeId=37383611111f, content=请问下有没有腺样囊腺癌的相关指南, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/02/18/81ff04c53a66053ece2d1fb796d2dac0.jpg, createdBy=cc1c2549075, createdName=maomao2019, createdTime=Wed Feb 20 11:39:34 CST 2019, time=2019-02-20, status=1, ipAttribution=)]
    2019-02-20 maomao2019

    请问下有没有腺样囊腺癌的相关指南

    0

相关资讯

Lancet oncol：Avelumab，抗PD-L1单克隆抗体，为对铂类不敏感的转移性尿路上皮癌患者带来新的希望。

现已批准抗程序性死亡配体1（PD-L1）和抗程序性死亡1类药物扩展用于治疗局部晚期或转移性尿路上皮细胞癌。人类抗PD-L1单克隆抗体，阿韦亚布（avelumab），已表现出抗肿瘤活性及安全性。现有研究人员进行研究，评估avelumab的安全性及其在用铂类药物治疗过的患者中的抗肿瘤活性。

Lancet：多西他赛联合雷莫芦单抗治疗晚期或转移尿路上皮细胞癌的疗效和安全性。

对铂类不敏感的晚期或转移尿路上皮细胞癌患者，少有不同机制的有效的治疗方案。Daniel P Petrylak及其同事对多西他赛联合雷莫芦单抗（人类IgG1 VEGFR-2拮抗剂）治疗晚期或转移尿路上皮细胞癌患者的效果和安全性进行评估。